Uniqure B.V. News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.04.20	uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors (GlobeNewswire)
30.03.20	uniQure to Participate in Multiple Upcoming Investor Conferences in April (GlobeNewswire)
02.03.20	uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters (GlobeNewswire)
27.02.20	uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference (GlobeNewswire)
04.02.20	uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire)
31.01.20	uniQure to Participate in Multiple Upcoming Industry Conferences in February (GlobeNewswire)
19.12.19	uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach (GlobeNewswire)
08.12.19	uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B (GlobeNewswire)
02.12.19	uniQure to Participate in Multiple Upcoming Industry Conferences in December (GlobeNewswire)
06.11.19	uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
05.11.19	uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy (GlobeNewswire)
01.11.19	uniQure to Participate in Multiple Upcoming Industry Conferences in November (GlobeNewswire)
31.10.19	uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec (GlobeNewswire)
28.10.19	uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress (GlobeNewswire)
27.09.19	uniQure to Participate in Multiple Upcoming Industry Conferences in October (GlobeNewswire)
06.09.19	uniQure Announces Pricing of its Public Offering (GlobeNewswire)
04.09.19	uniQure Announces Proposed Public Offering (GlobeNewswire)
03.09.19	uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B (GlobeNewswire)
30.08.19	uniQure to Participate in Multiple Upcoming Industry Conferences in September (GlobeNewswire)
20.08.19	uniQure Announces Leadership Promotions and Executive Transition (GlobeNewswire)
29.07.19	uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress (GlobeNewswire)
26.07.19	uniQure to Participate in Multiple Upcoming Industry Conferences (GlobeNewswire)
06.07.19	uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B (GlobeNewswire)
21.06.19	uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) (GlobeNewswire)
31.05.19	uniQure to Participate in Multiple Upcoming Industry Conferences (GlobeNewswire)
22.05.19	uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease (GlobeNewswire)
10.05.19	uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B (GlobeNewswire)
02.05.19	uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting (GlobeNewswire)
01.05.19	uniQure to Participate in Multiple Upcoming Industry Conferences (GlobeNewswire)
29.04.19	uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress (GlobeNewswire)
15.04.19	uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
08.04.19	uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease (GlobeNewswire)
29.03.19	uniQure to Participate in Multiple Upcoming Industry Conferences (GlobeNewswire)
01.03.19	uniQure to Participate in Multiple Upcoming Industry Conferences (GlobeNewswire)
28.02.19	uniQure Announces 2018 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
27.02.19	uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference (GlobeNewswire)
15.02.19	uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids (GlobeNewswire)
08.02.19	uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B (GlobeNewswire)
04.02.19	uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B (GlobeNewswire)
30.01.19	uniQure to Participate in Multiple Upcoming Industry Conferences (GlobeNewswire)
22.01.19	uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease (GlobeNewswire)
10.01.19	10 Gene Therapy Companies Unignorable In 2019 (RTTNews)
03.12.18	uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B (GlobeNewswire)
19.11.18	uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day (GlobeNewswire)
16.11.18	QURE In The Pink, ARNA Heartens Investors, ELOX Up Over 40% This Month (RTTNews)
15.11.18	uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B (GlobeNewswire)
06.11.18	uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress (GlobeNewswire)
05.11.18	uniQure to Host Research & Development Day on Monday, November 19 in New York City (GlobeNewswire)
31.10.18	uniQure to Participate in Multiple Upcoming Industry Conferences (GlobeNewswire)
18.10.18	uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Uniqure B.V.

Aktien Top/Flop

Meistgelesene Nachrichten